Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer - Top-Institutions - MDSpire

Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer

  • By

  • José P. Leone

  • Julieta Leone

  • Pietro De Placido

  • Faina Nakhlis

  • Ilana Schlam

  • Kelly A. Hirko

  • Aditi Hazra

  • Elizabeth Troll

  • Jennifer R. Bellon

  • Carlos T. Vallejo

  • Nancy U. Lin

  • Sara M. Tolaney

  • Filipa Lynce

  • April 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Breast Oncology
    • Surgical Oncology
    • Radiation Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Breast Cancer Research

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Surgical Oncology
    • Radiation Oncology
    • Breast Oncology

  • #4

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Breast Oncology
    • Medical Oncology
    • Clinical Research

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Breast Oncology
    • Radiation Oncology
    • Clinical Trials

Original Source(s)

Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer

  • by José P. Leone, Julieta Leone, Pietro De Placido, Faina Nakhlis, Ilana Schlam, Kelly A. Hirko, Aditi Hazra, Elizabeth Troll, Jennifer R. Bellon, Carlos T. Vallejo, Nancy U. Lin, Sara M. Tolaney, Filipa Lynce

  • April 9, 2026

Related Content

Overcoming immunotherapy resistance in triple-negative breast cancer: a critical review of mast cell plasticity, metabolic reprogramming, and organoid models

Prognostic Evaluation Using Nutrition-Inflammation Biomarkers from Routine Blood Tests in Metastatic Breast Cancer: A Boruta Algorithm-Optimized Feature Selection Study

Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

  • by

  • May 25, 2026

  • 9 min